Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes

Drug Metabolism and Disposition

Volumn 28, Issue 6, 2000, Pages 655-660

  Choo, Edna F ^a   Leake, Brenda ^a   Wandel, Christoph ^a   Imamura, Hitoshi ^a   Wood, Alastair J J ^a   Wilkinson, Grant R ^a   Kim, Richard B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [3 [4 (10,11 DIFLUOROMETHANODIBENZOSUBER 5 YL)PIPERAZIN 1 YL] 2 HYDROXYPROPOXY]QUINILONE TRIHYDROCHLORIDE; CYCLOSPORIN A; DIGOXIN; GLYCOPROTEIN P; INDINAVIR; KETOCONAZOLE; NELFINAVIR; PIPERAZINE DERIVATIVE; PROTEINASE INHIBITOR; QUINIDINE; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; ZOSUQUIDAR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TESTIS; VIRUS REPLICATION;

ANIMALS; BIOLOGICAL TRANSPORT; BRAIN; CACO-2 CELLS; DIBENZOCYCLOHEPTENES; HIV PROTEASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; P-GLYCOPROTEIN; QUINOLINES; TESTIS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0034121122     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Ambudkar SV, Dey S, Hrycyna CA. Ramachandra M, Pastan I and Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398.
2. Ambudkar SV and Gottesman MM (1998) Methods in Enzymology-ABC Transporters: Biochemical, Cellular and Molecular Aspects, vol 292, Academic Press, London.
3. Bellamy WT (1996) P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol 36:161-183.
4. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Henset S, Smyth JF, Brampton MH and Bleehen NM (1996) Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14:610-618.
5. Bossuyt X, Müller M, Hagenbuch B and Meier PJ (1996a) Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther 276:891-896.
6. Bossuyt X, Müller M and Meier PJ (1996b) Multispecific amphipathic substrate transport by an organic anion transporter of human liver. J Hepatol 25:733-738.
7. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR and Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698.
8. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
9. Dantzig AH, Shepard RL, Cao J, Law KL. Ehlhardt WJ, Baughman TM, Bumol TF and Starling JJ (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56:4171-4179.
10. Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, Binkley SN, Kuhfeld MT, Starling JJ and Wrighton SA (1999) Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 290:854-862.
11. Drewe J, Gutmann H, Fricker G, Torok M, Beglinger C and Huwyler J (1999) HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 57:1147-1152.
12. Fischer V, Rodriguez-Gascon A, Heitz F, Tynes R, Hauck C, Cohen D and Vickers AE (1998) The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A: Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 26:802-811.
13. Ford JM (1996) Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer 32A:991-1001.
14. Ford JM and Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155-199.
15. Gao B, Stieger B, Noe B, Fritschy JM and Meier PJ (1999) Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 47:1255-1264.
16. Groothuis DR and Levy RM (1997) The entry of antiviral and antiretroviral drugs into the central nervous system. J Neurovirol 3:387-400.
17. Holash JA, Harik SI, Perry G and Stewart PA (1993) Barrier properties of testes microvessels. Proc Natl Acad Sci USA 90:11069-11073.
18. Kim AE, Dintaman JM, Waddell DS and Silverman JA (1998) Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 286:1439-1445.
19. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM and Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
20. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ and Wilkinson GR (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16:408-414.
21. Kolson DL, Lavi E and Gonzalez-Scarano F (1998) The effects of human immunodeficiency virus in the central nervous system. Adv Virus Res 50:1-47.
22. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y and Endou H (1999) Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem 274:13675-13680.
23. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I and Dey S (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-3601.
24. Lin JH (1997) Human immunodeficiency virus protease inhibitors: From drug to clinical studies. Adv Drug Delivery Syst 27:215-233.
25. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P and Schinkel AH (1997) Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 100:2430-2436.
26. Noe B, Hagenbuch B, Stieger B and Meier PJ (1997) Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci USA 94:10346-10350.
27. Piketty C, Race E, Castiel P, Belec L, Peytavin G, Si-Mohamed A, Gonzalez-Canali G, Weiss L, Clavel F and Kazatchkine MD (1999) Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 13:F71-F77.
28. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR and Woolley JL (1999) Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 16:1206-1212.
29. Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM, van Kapel J, Groenewegen A, Charnick S, Zittoun R and Lowenberg B (1996) Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma: A phase I study. Leukemia 10:1741-1750.
30. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc Natl Acad Sci USA 84:7735-7738.
31. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
32. Wacher VJ, Wu C-Y and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
33. Wandel C, Kim RB, Kajiji S, Ghebreselasie K, Guengerich FP, Wilkinson GR and Wood AJJ (1999) P-glycoprotein and cytochrome P450 3A inhibition: Dissociation of inhibitory potencies. Cancer Res 59:3944-3948.
34. Wu EY, Zhang KE, Sandoval TM, Grettenberger HM, Hee BR, Lee CA, Webber S and Shetty BV (1998) Cytochrome P450 isoforms involved in the metabolism of nelfinavir mesylate, an HIV-1 protease inhibitor. Proceedings of the 5th International ISSX Meeting; Cairns, Australia, October 25-29, 1999.
35. Zhang H, Dornadula G, Beumont M, Livornese LJ, Van Uitert B, Henning K and Pomerantz RJ (1998) Human immunodeficiency virus Type I in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 339:1803-1809.